TheraCryf

Evgen Pharma is a pioneering biotechnology company at the forefront of sulforaphane research and drug development, specializing in innovative treatments for cancer and inflammation. With a strong focus on oncology and behavioral brain disorders, the company's initiatives aim to navigate the complexities of drug development while contributing to groundbreaking therapeutics. TheraCryf plc, a clinical-stage subsidiary, is actively developing a new generation of therapeutics by harnessing compelling data sets to secure partnerships with mid-sized and large pharmaceutical companies.

Led by an experienced team including CEO Dr. Huw Jones and other seasoned professionals, Evgen Pharma boasts a wealth of knowledge in biotechnology and pharmaceutical sectors. Their approach integrates robust scientific expertise with strategic business development, ensuring that they are well-positioned to meet the urgent medical needs of patients. Through collaborative efforts with expert advisors and a commitment to innovative research, Evgen Pharma is dedicated to advancing the field of drug development, potentially offering new hope for those affected by critical health challenges.